Inventiva
IVAIVA · Stock Price
Historical price data
Overview
Inventiva's mission is to develop innovative, oral small molecule therapies for significant unmet medical needs in fibrotic, lysosomal, and oncologic diseases. Its key achievement is the advancement of lanifibranor, a novel pan-PPAR agonist, into a pivotal Phase III trial for MASH/NASH, supported by strong Phase IIb data and regulatory recognition. The company's strategy is built on its proprietary drug discovery platform, strategic partnerships for development and commercialization, and a focus on oral administration to maximize patient compliance and commercial potential.
Technology Platform
Integrated drug discovery platform specializing in nuclear receptor, transcription factor, and epigenetic modulation, supported by a proprietary chemical library of 240,000 molecules and in-house R&D capabilities.
Pipeline
7| Drug | Indication | Stage | Watch |
|---|---|---|---|
| IVA337 + Placebo | NASH - Nonalcoholic Steatohepatitis | Phase 3 | |
| IVA337 + IVA337 + Placebo | Non-Alcoholic Steatohepatitis (NASH) | Phase 2 | |
| IVA337 + Placebo | Scleroderma, Diffuse | Phase 2 | |
| Odiparcil | Mucopolysaccharidosis VI | Phase 2 | |
| Lanifibranor | Nonalcoholic Fatty Liver Disease (NAFLD) | Phase 2 |
Funding History
2Opportunities
Risk Factors
Competitive Landscape
Lanifibranor faces competition from multiple late-stage MASH therapies with diverse mechanisms (FXR, FGF21, THR-β agonists). Its key differentiation is the pan-PPAR approach aiming for comprehensive efficacy on metabolism, inflammation, and fibrosis, supported by Breakthrough Therapy designation.